GlassScriptPhysician profile
Morgan Leasure
NPI 1306532635
$5,104.46
in general payments reported to CMS, 2019-2025
54 companies · $2,293 in 2025
The $2,293 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.35 · 2023: $861 · 2024: $1,918 · 2025: $2,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,973 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,973.11 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $344.78 | 2023-2025 | |
| Eisai INC. | $323.11 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $314.30 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Geron Corporation | $272.13 | 2024-2025 | Rytelo |
| Daiichi Sankyo INC. | $255.89 | 2023-2025 | Enhertu, Datroway |
| Pfizer INC. | $254.72 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $217.47 | 2023-2025 | Ninlaro, Iclusig, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $199.42 | 2022-2025 | Enhertu, Lynparza, Tagrisso |
| Janssen Biotech, INC. | $198.98 | 2023-2025 | Darzalex, Erleada, Akeega |
| Incyte Corporation | $198.54 | 2023-2025 | Jakafi, Pemazyre, Monjuvi |
| Sobi, INC | $181.51 | 2024-2025 | |
| Abbvie INC. | $179.98 | 2023-2025 | |
| Astellas Pharma US INC | $129.72 | 2023-2025 | Vyloy, Padcev |
| Genentech USA, INC. | $124.53 | 2023-2024 | Venclexta, Tecentriq, Phesgo |
| Lilly USA, LLC | $119.36 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $106.59 | 2023-2025 | |
| Glaxosmithkline, LLC. | $104.18 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Taiho Oncology, INC. | $102.90 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $87.50 | 2023-2025 | Alymsys, Avastin, Neupogen |
| Celgene Corporation | $83.71 | 2024-2025 | Reblozyl |
| Beigene USA, INC. | $83.27 | 2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $73.12 | 2025 | Libtayo |
| Stemline Therapeutics INC. | $71.99 | 2024-2025 | Orserdu, Elzonris |
| Exelixis INC. | $68.39 | 2025 | Cabometyx |
| Tempus Ai, INC | $66.77 | 2025 | Xt Cdx |
| Genmab U.S., INC. | $63.31 | 2023-2025 | Epkinly, Tivdak |
| Beone Medicines USA, INC. | $61.44 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $60.22 | 2025 | Braftovi, Mektovi, Lorbrena |
| Recordati_rare_diseases_inc. | $55.32 | 2023-2024 | Sylvant |
| Pharmacosmos Therapeutics INC. | $49.51 | 2024-2025 | Monoferric |
| Seagen INC. | $44.22 | 2023 | Padcev, Adcetris |
| Accord Healthcare, INC. | $43.42 | 2025 | |
| Aveo Pharmaceuticals, INC. | $41.28 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $40.54 | 2023-2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $37.46 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $36.96 | 2024 | Onivyde |
| Springworks Therapeutics, INC. | $35.42 | 2024-2025 | Gomekli, Ogsiveo |
| Adaptive Biotechnologies Corporation | $33.36 | 2025 | Clonoseq |
| Iovance Biotherapeutics, INC. | $31.38 | 2024-2025 | Amtagvi |
| Ge Healthcare | $25.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.88 | 2025 | |
| Octapharma USA, INC. | $24.74 | 2025 | Octagam Immune Globulin (Human) |
| G1 Therapeutics, INC. | $24.39 | 2023 | Cosela |
| Tersera Therapeutics LLC | $24.25 | 2025 | Xermelo |
| Menarini Silicon Biosystems, INC. | $21.75 | 2023 | Cellsearch |
| Pharmaessentia USA Corporation | $20.90 | 2023 | Besremi |
| Sun Pharmaceutical Industries INC. | $20.78 | 2024 | |
| Coherus Oncology, INC. | $20.65 | 2025 | Loqtorzi |
| Pharming Healthcare, INC. | $20.01 | 2023 | Ruconest |
| Blueprint Medicines Corporation | $18.39 | 2024 | Ayvakit |
| Spectrum Pharmaceuticals INC. | $16.91 | 2023 | Rolvedon |
| Amgen INC. | $16.70 | 2023 | Lumakras |
| Sumitomo Pharma America, INC. | $14.15 | 2023 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2024 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Leasure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.